MedPath

Lubiprostone

Generic Name
Lubiprostone
Brand Names
Amitiza
Drug Type
Small Molecule
Chemical Formula
C20H32F2O5
CAS Number
136790-76-6
Unique Ingredient Identifier
7662KG2R6K

Overview

Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. Activation of these channels promotes the secretion of a chloride-rich fluid that soften the stool, increase gastrointestinal motility, and induce spontaneous bowel movements (SBM).

Indication

Lubiprostone is indicated for the treatment of adult patients with chronic idiopathic constipation, or opioid-induced constipation in patients with chronic non-cancer pain. It is also indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in female patients ≥18 years old.

Associated Conditions

  • Irritable Bowel Syndrome With Constipation (IBS-C)
  • Opioid Induced Constipation (OIC)
  • Chronic idiopathic constipation (CIC)

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Quality Care Products, LLC
83008-001
ORAL
24 ug in 1 1
4/20/2023
Zydus Pharmaceuticals USA Inc.
70710-1642
ORAL
24 ug in 1 1
3/27/2023
Zydus Lifesciences Limited
70771-1763
ORAL
8 ug in 1 1
3/24/2023
Amneal Pharmaceuticals LLC
65162-841
ORAL
8 ug in 1 1
2/7/2023
Par Pharmaceutical Inc.
0254-3029
ORAL
24 ug in 1 1
11/1/2020
SPECGX LLC
23635-524
ORAL
24 ug in 1 1
1/31/2024
Direct_Rx
72189-410
ORAL
8 ug in 1 1
1/12/2023
Lake Erie Medical DBA Quality Care Products LLC
35356-500
ORAL
24 ug in 1 1
12/19/2018
Sun Pharmaceutical Industries, Inc.
63304-352
ORAL
24 ug in 1 1
1/1/2023
Teva Pharmaceuticals, Inc.
0480-3479
ORAL
8 ug in 1 1
5/27/2022

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
AMITIZA
02447363
Capsule - Oral
24 MCG
N/A

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.